- Home
- AXGN
AXGN
Axogen Inc.
as of 01-02-2026 12:11pm EST
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | ALACHUA |
| Market Cap: | 1.4B | IPO Year: | N/A |
| Target Price: | $33.67 | AVG Volume (30 days): | 922.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.21 - $34.24 | Next Earning Date: | 10-29-2025 |
| Revenue: | $214,709,000 | Revenue Growth: | 18.72% |
| Revenue Growth (this year): | 21.6% | Revenue Growth (next year): | 15.83% |
AI-Powered AXGN Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Axogen Inc. (AXGN)
Director
Avg Cost/Share
$29.55
Shares
46,653
Total Value
$1,378,475.93
Owned After
28,405
Director
Avg Cost/Share
$29.31
Shares
43,684
Total Value
$1,280,465.41
Owned After
112,074
Avg Cost/Share
$29.86
Shares
14,812
Total Value
$442,293.73
Owned After
31,376
SEC Form 4
Director
Avg Cost/Share
$29.98
Shares
21,686
Total Value
$650,189.65
Owned After
0
EVP & General Counsel
Avg Cost/Share
$31.21
Shares
9,278
Total Value
$289,547.82
Owned After
31,507
SEC Form 4
Chief Innovation Officer
Avg Cost/Share
$31.21
Shares
19,517
Total Value
$609,086.54
Owned After
241,132
SEC Form 4
Director
Avg Cost/Share
$30.98
Shares
25,108
Total Value
$777,770.52
Owned After
10,860
Director
Avg Cost/Share
$29.61
Shares
21,399
Total Value
$633,709.99
Owned After
13,528
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$31.21
Shares
61,463
Total Value
$1,918,137.30
Owned After
88,537
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Weiler Kathy Johnson | AXGN | Director | Dec 16, 2025 | Sell | $29.55 | 46,653 | $1,378,475.93 | 28,405 | |
| Wendell Amy McBride | AXGN | Director | Dec 16, 2025 | Sell | $29.31 | 43,684 | $1,280,465.41 | 112,074 | |
| Hartley Lindsey Marie | AXGN | CFO | Dec 15, 2025 | Sell | $29.86 | 14,812 | $442,293.73 | 31,376 | |
| JOHNSON JOHN | AXGN | Director | Dec 9, 2025 | Sell | $29.98 | 21,686 | $650,189.65 | 0 | |
| Began Marc A | AXGN | EVP & General Counsel | Dec 9, 2025 | Sell | $31.21 | 9,278 | $289,547.82 | 31,507 | |
| DeVinney Erick Wayne | AXGN | Chief Innovation Officer | Dec 9, 2025 | Sell | $31.21 | 19,517 | $609,086.54 | 241,132 | |
| Kemp Jens | AXGN | Chief Marketing Officer | Dec 9, 2025 | Sell | $31.21 | 8,156 | $254,532.45 | 46,030 | |
| TYNDALL JOSEPH A. | AXGN | Director | Dec 9, 2025 | Sell | $30.98 | 25,108 | $777,770.52 | 10,860 | |
| THOMAS PAUL | AXGN | Director | Dec 9, 2025 | Sell | $29.61 | 21,399 | $633,709.99 | 13,528 | |
| DALE MICHAEL D | AXGN | Chief Executive Officer | Dec 9, 2025 | Sell | $31.21 | 61,463 | $1,918,137.30 | 88,537 |
Compare AXGN vs Leading Stocks
See how AXGN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AXGN Axogen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.